Cargando…

Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015

In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieck, Thorsten, Feig, Marcel, an der Heiden, Matthias, Siedler, Anette, Wichmann, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434885/
https://www.ncbi.nlm.nih.gov/pubmed/28488996
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521
_version_ 1783237133165658112
author Rieck, Thorsten
Feig, Marcel
an der Heiden, Matthias
Siedler, Anette
Wichmann, Ole
author_facet Rieck, Thorsten
Feig, Marcel
an der Heiden, Matthias
Siedler, Anette
Wichmann, Ole
author_sort Rieck, Thorsten
collection PubMed
description In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional hazard models to estimate VE under various conditions and compared the risk of acquiring varicella among unvaccinated children in regions with high vs low vaccination coverage (VC). Among 1.4 million children we identified 29,404 varicella cases over a maximum follow-up of 8 years post-vaccination. One-dose VE was 81.9% (95% confidence interval (CI): 81.4–82.5), two-dose VE 94.4% (95% CI: 94.2–94.6). With dose one given 1–27 days after measles-containing vaccine (MCV), one-dose VE was 32.2% (95% CI: 10.4–48.6), two-dose VE 92.8% (95% CI: 84.8–96.6). VE was not associated with age at vaccination (11–14 vs ≥ 15 months), time since vaccination, or vaccine type. Unvaccinated children had a twofold higher risk of acquiring varicella in low VC regions. Our system generated valuable data, showing that two-dose varicella vaccination provides good protection for at least 8 years. Unvaccinated children benefit from herd effects. When the first varicella vaccine dose is given shortly after MCV, a second dose is essential.
format Online
Article
Text
id pubmed-5434885
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-54348852017-05-30 Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 Rieck, Thorsten Feig, Marcel an der Heiden, Matthias Siedler, Anette Wichmann, Ole Euro Surveill Research Article In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional hazard models to estimate VE under various conditions and compared the risk of acquiring varicella among unvaccinated children in regions with high vs low vaccination coverage (VC). Among 1.4 million children we identified 29,404 varicella cases over a maximum follow-up of 8 years post-vaccination. One-dose VE was 81.9% (95% confidence interval (CI): 81.4–82.5), two-dose VE 94.4% (95% CI: 94.2–94.6). With dose one given 1–27 days after measles-containing vaccine (MCV), one-dose VE was 32.2% (95% CI: 10.4–48.6), two-dose VE 92.8% (95% CI: 84.8–96.6). VE was not associated with age at vaccination (11–14 vs ≥ 15 months), time since vaccination, or vaccine type. Unvaccinated children had a twofold higher risk of acquiring varicella in low VC regions. Our system generated valuable data, showing that two-dose varicella vaccination provides good protection for at least 8 years. Unvaccinated children benefit from herd effects. When the first varicella vaccine dose is given shortly after MCV, a second dose is essential. European Centre for Disease Prevention and Control (ECDC) 2017-04-27 /pmc/articles/PMC5434885/ /pubmed/28488996 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research Article
Rieck, Thorsten
Feig, Marcel
an der Heiden, Matthias
Siedler, Anette
Wichmann, Ole
Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title_full Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title_fullStr Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title_full_unstemmed Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title_short Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
title_sort assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, germany, 2006 to 2015
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434885/
https://www.ncbi.nlm.nih.gov/pubmed/28488996
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521
work_keys_str_mv AT rieckthorsten assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015
AT feigmarcel assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015
AT anderheidenmatthias assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015
AT siedleranette assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015
AT wichmannole assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015